Clinical trials: Wound Infection Bacterial
- Condition Wound Infection Bacterial
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Surgical Site Infection
Impact of Pre-surgical Nasal Bacterial Reduction on Postoperative Surgical Site Infections / Standard Care Change
Patients presenting in the Emergency Department or admitted to the hospital with displaced hip fractures who require hemiarthroplasty or open reduction internal fixation or with spinal instability/fractures in need of urgent…
- Trial name
- NCT01148030
- Testing
- 3M Skin and Nasal Antiseptic
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- 3M
Staphylococcus Aureus, Orthopaedic Surgery
Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery
Surgical site infections in orthopaedic surgery are a major problem. Decolonization has been suggested to reduce infection rates.
- Conditions
- Staphylococcus Aureus, Orthopaedic Surgery, Surgical Site Infection, Prevention
- Trial name
- DECO-SSI (NCT03962907)
- Testing
- Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun, BACTROBAN® Nasal ong
- Where
- Switzerland
- Volunteers
- 1,318 people
- Sponsor
- Lindenhofgruppe AG
Orthopedic Disorders, Surgical Site Infection
Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial
Surgical site infections are a major postoperative complication and are mostly due to colonization with endogenous germs, like Staphylococcus aureus, Staphylococcus epidermidis or Propionibacterium acnes.
- Trial name
- DECO-SSI (NCT02560155)
- Testing
- Mupirocin 2% nasal ointement, Chlorhexidine sol 4%
- Where
- Switzerland
- Volunteers
- 1,300 people
- Sponsor
- Lindenhofgruppe AG
Infections, Bacterial
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 (WP2) and Workgroup 1.
- Trial name
- NCT01587768
- Testing
- Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Tetanus
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred.
- Trial name
- NCT07107932
- Testing
- Siltartoxatug Injection (Brand name: Sintetol®)
- Where
- 4 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.